메뉴 건너뛰기




Volumn 29, Issue 2, 2015, Pages 75-89

Chimeric antigen receptor-engineered t cells for the treatment of metastatic prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 84937760760     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0122-9     Document Type: Article
Times cited : (60)

References (156)
  • 1
    • 0024166189 scopus 로고
    • Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma - A preliminary report
    • 1:STN:280:DyaL1M%2FntVKmsw%3D%3D 3264384
    • Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma - a preliminary report. New Engl J Med. 1988;319(25):1676-80.
    • (1988) New Engl J Med. , vol.319 , Issue.25 , pp. 1676-1680
    • Rosenberg, S.A.1    Packard, B.S.2    Aebersold, P.M.3    Solomon, D.4    Topalian, S.L.5    Toy, S.T.6
  • 2
    • 20244366111 scopus 로고    scopus 로고
    • Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    • 1:CAS:528:DC%2BD2MXjsVyhsrs%3D 15800326
    • Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-57.
    • (2005) J Clin Oncol. , vol.23 , Issue.10 , pp. 2346-2357
    • Dudley, M.E.1    Wunderlich, J.R.2    Yang, J.C.3    Sherry, R.M.4    Topalian, S.L.5    Restifo, N.P.6
  • 3
    • 33749624177 scopus 로고    scopus 로고
    • Cancer regression in patients after transfer of genetically engineered lymphocytes
    • 2267026 1:CAS:528:DC%2BD28XhtVCiurrK 16946036
    • Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9.
    • (2006) Science. , vol.314 , Issue.5796 , pp. 126-129
    • Morgan, R.A.1    Dudley, M.E.2    Wunderlich, J.R.3    Hughes, M.S.4    Yang, J.C.5    Sherry, R.M.6
  • 4
    • 84928912377 scopus 로고    scopus 로고
    • A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response
    • 1:CAS:528:DC%2BC2MXjsF2itrc%3D 25538264
    • Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019-27.
    • (2015) Clin Cancer Res. , vol.21 , Issue.5 , pp. 1019-1027
    • Robbins, P.F.1    Kassim, S.H.2    Tran, T.L.3    Crystal, J.S.4    Morgan, R.A.5    Feldman, S.A.6
  • 5
    • 79952304769 scopus 로고    scopus 로고
    • Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    • 3068063 21282551
    • Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-24.
    • (2011) J Clin Oncol. , vol.29 , Issue.7 , pp. 917-924
    • Robbins, P.F.1    Morgan, R.A.2    Feldman, S.A.3    Yang, J.C.4    Sherry, R.M.5    Dudley, M.E.6
  • 6
    • 84872577768 scopus 로고    scopus 로고
    • Genetically engineered T cells for the treatment of cancer
    • 3607417 1:CAS:528:DC%2BC3sXhsVaktL4%3D 23198862
    • Essand M, Loskog ASI. Genetically engineered T cells for the treatment of cancer. J Intern Med. 2013;273(2):166-81.
    • (2013) J Intern Med. , vol.273 , Issue.2 , pp. 166-181
    • Essand, M.1    Loskog, A.S.I.2
  • 7
    • 79955517235 scopus 로고    scopus 로고
    • CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
    • 3083795 1:CAS:528:DC%2BC3MXlvFKnt7o%3D 21540550
    • Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-6.
    • (2011) J Clin Invest. , vol.121 , Issue.5 , pp. 1822-1826
    • Savoldo, B.1    Ramos, C.A.2    Liu, E.3    Mims, M.P.4    Keating, M.J.5    Carrum, G.6
  • 8
    • 76349087378 scopus 로고    scopus 로고
    • Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication
    • 2839303 1:CAS:528:DC%2BD1MXhtFGrsb7P 19773745
    • Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413-20.
    • (2010) Mol Ther. , vol.18 , Issue.2 , pp. 413-420
    • Zhong, X.S.1    Matsushita, M.2    Plotkin, J.3    Riviere, I.4    Sadelain, M.5
  • 9
    • 74949124101 scopus 로고    scopus 로고
    • 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies
    • 2861957 1:CAS:528:DC%2BC3cXhvVyqtb4%3D 19719389
    • Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010;21(1):75-86.
    • (2010) Hum Gene Ther. , vol.21 , Issue.1 , pp. 75-86
    • Tammana, S.1    Huang, X.2    Wong, M.3    Milone, M.C.4    Ma, L.5    Levine, B.L.6
  • 10
    • 55549145071 scopus 로고    scopus 로고
    • Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma
    • 2749734 1:CAS:528:DC%2BD1cXhtlCjtLrF 18978797
    • Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-70.
    • (2008) Nat Med. , vol.14 , Issue.11 , pp. 1264-1270
    • Pule, M.A.1    Savoldo, B.2    Myers, G.D.3    Rossig, C.4    Russell, H.V.5    Dotti, G.6
  • 11
    • 62549097817 scopus 로고    scopus 로고
    • Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    • 2651342 1:CAS:528:DC%2BD1MXivF2jsbw%3D 19211796
    • Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci. 2009;106(9):3360-5.
    • (2009) Proc Natl Acad Sci , vol.106 , Issue.9 , pp. 3360-3365
    • Carpenito, C.1    Milone, M.C.2    Hassan, R.3    Simonet, J.C.4    Lakhal, M.5    Suhoski, M.M.6
  • 12
    • 70350726110 scopus 로고    scopus 로고
    • Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
    • 2805264 1:CAS:528:DC%2BD1MXkvVWqsLk%3D 19384291
    • Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-64.
    • (2009) Mol Ther. , vol.17 , Issue.8 , pp. 1453-1464
    • Milone, M.C.1    Fish, J.D.2    Carpenito, C.3    Carroll, R.G.4    Binder, G.K.5    Teachey, D.6
  • 13
    • 34548485103 scopus 로고    scopus 로고
    • Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
    • 1:CAS:528:DC%2BD2sXpsV2kurw%3D 17685852
    • Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18(8):712-25.
    • (2007) Hum Gene Ther. , vol.18 , Issue.8 , pp. 712-725
    • Wang, J.1    Jensen, M.2    Lin, Y.3    Sui, X.4    Chen, E.5    Lindgren, C.G.6
  • 14
    • 76749120309 scopus 로고    scopus 로고
    • A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
    • 1:CAS:528:DC%2BD1MXht1ymtbzI 19843940
    • Zhao YB, Wang QJ, Yang SC, Kochenderfer JN, Zheng ZL, Zhong XS, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563-74.
    • (2009) J Immunol. , vol.183 , Issue.9 , pp. 5563-5574
    • Zhao, Y.B.1    Wang, Q.J.2    Yang, S.C.3    Kochenderfer, J.N.4    Zheng, Z.L.5    Zhong, X.S.6
  • 15
    • 84860333968 scopus 로고    scopus 로고
    • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results
    • 3350361 1:CAS:528:DC%2BC38Xms1alt7w%3D 22308288
    • Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940-50.
    • (2012) Blood. , vol.119 , Issue.17 , pp. 3940-3950
    • Till, B.G.1    Jensen, M.C.2    Wang, J.3    Qian, X.4    Gopal, A.K.5    Maloney, D.G.6
  • 16
    • 80051720194 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    • 3387277 1:CAS:528:DC%2BC3MXhtV2lu7nP 21830940
    • Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-33.
    • (2011) N Engl J Med. , vol.365 , Issue.8 , pp. 725-733
    • Porter, D.L.1    Levine, B.L.2    Kalos, M.3    Bagg, A.4    June, C.H.5
  • 17
    • 80051775476 scopus 로고    scopus 로고
    • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    • 3393096 1:CAS:528:DC%2BC3MXhtFOisL3N 21832238
    • Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
    • (2011) Sci Transl Med. , vol.3 , Issue.95 , pp. 95ra73
    • Kalos, M.1    Levine, B.L.2    Porter, D.L.3    Katz, S.4    Grupp, S.A.5    Bagg, A.6
  • 18
    • 84908073316 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells for sustained remissions in leukemia
    • 4267531 1:CAS:528:DC%2BC2cXitVSls73K 25317870
    • Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17.
    • (2014) N Engl J Med. , vol.371 , Issue.16 , pp. 1507-1517
    • Maude, S.L.1    Frey, N.2    Shaw, P.A.3    Aplenc, R.4    Barrett, D.M.5    Bunin, N.J.6
  • 19
    • 84896335556 scopus 로고    scopus 로고
    • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    • 24553386
    • Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
    • (2014) Sci Transl Med. , vol.6 , Issue.224 , pp. 224ra25
    • Davila, M.L.1    Riviere, I.2    Wang, X.3    Bartido, S.4    Park, J.5    Curran, K.6
  • 20
    • 84923118622 scopus 로고    scopus 로고
    • Chemotherapy-refractory diffuse large B-cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
    • 1:CAS:528:DC%2BC2MXktlCntr4%3D 25154820
    • Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-9.
    • (2015) J Clin Oncol. , vol.33 , Issue.6 , pp. 540-549
    • Kochenderfer, J.N.1    Dudley, M.E.2    Kassim, S.H.3    Somerville, R.P.4    Carpenter, R.O.5    Stetler-Stevenson, M.6
  • 21
    • 84923019006 scopus 로고    scopus 로고
    • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
    • 1:CAS:528:DC%2BC2cXhslGjtLbM 25319501
    • Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-28.
    • (2015) Lancet. , vol.385 , Issue.9967 , pp. 517-528
    • Lee, D.W.1    Kochenderfer, J.N.2    Stetler-Stevenson, M.3    Cui, Y.K.4    Delbrook, C.5    Feldman, S.A.6
  • 23
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • 1:CAS:528:DC%2BC3cXhtVGlurrN 20818862
    • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
    • (2010) N Engl J Med. , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3    Berger, E.R.4    Small, E.J.5    Penson, D.F.6
  • 24
    • 77949895922 scopus 로고    scopus 로고
    • Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
    • 2834462 1:CAS:528:DC%2BC3cXktF2ltLw%3D 20100959
    • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-105.
    • (2010) J Clin Oncol. , vol.28 , Issue.7 , pp. 1099-1105
    • Kantoff, P.W.1    Schuetz, T.J.2    Blumenstein, B.A.3    Glode, L.M.4    Bilhartz, D.L.5    Wyand, M.6
  • 25
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • 1:CAS:528:DC%2BC38XksVegtrw%3D 22437870
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.
    • (2012) Nat Rev Cancer. , vol.12 , Issue.4 , pp. 252-264
    • Pardoll, D.M.1
  • 26
    • 84255204457 scopus 로고    scopus 로고
    • Prostate cancer and inflammation: The evidence
    • 4029103 22212087
    • Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199-215.
    • (2012) Histopathology. , vol.60 , Issue.1 , pp. 199-215
    • Sfanos, K.S.1    De Marzo, A.M.2
  • 27
    • 37249067503 scopus 로고    scopus 로고
    • CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer
    • 1:CAS:528:DC%2BD2sXhtlyit7fF 18056169
    • Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13(23):6947-58.
    • (2007) Clin Cancer Res. , vol.13 , Issue.23 , pp. 6947-6958
    • Kiniwa, Y.1    Miyahara, Y.2    Wang, H.Y.3    Peng, W.4    Peng, G.5    Wheeler, T.M.6
  • 28
    • 48849103649 scopus 로고    scopus 로고
    • Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
    • 3082357 1:CAS:528:DC%2BD1cXmslygs70%3D 18519750
    • Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14(11):3254-61.
    • (2008) Clin Cancer Res. , vol.14 , Issue.11 , pp. 3254-3261
    • Sfanos, K.S.1    Bruno, T.C.2    Maris, C.H.3    Xu, L.4    Thoburn, C.J.5    Demarzo, A.M.6
  • 29
    • 33750807427 scopus 로고    scopus 로고
    • CD4+ CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
    • 1:CAS:528:DC%2BD28XhtFGrtrfM 17082659
    • Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al. CD4+ CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177(10):7398-405.
    • (2006) J Immunol. , vol.177 , Issue.10 , pp. 7398-7405
    • Miller, A.M.1    Lundberg, K.2    Ozenci, V.3    Banham, A.H.4    Hellstrom, M.5    Egevad, L.6
  • 30
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • 2722174 1:CAS:528:DC%2BD1MXps1enu7w%3D 19581407
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-25.
    • (2009) J Exp Med. , vol.206 , Issue.8 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3    Korman, A.J.4    Allison, J.P.5
  • 31
    • 84880508629 scopus 로고    scopus 로고
    • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study
    • 3707423 1:STN:280:DC%2BC3srgt1Cmtg%3D%3D 23535954
    • Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813-21.
    • (2013) Ann Oncol. , vol.24 , Issue.7 , pp. 1813-1821
    • Slovin, S.F.1    Higano, C.S.2    Hamid, O.3    Tejwani, S.4    Harzstark, A.5    Alumkal, J.J.6
  • 32
    • 84901641673 scopus 로고    scopus 로고
    • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial
    • 1:CAS:528:DC%2BC2cXotFOrs74%3D 24831977
    • Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12.
    • (2014) Lancet Oncol. , vol.15 , Issue.7 , pp. 700-712
    • Kwon, E.D.1    Drake, C.G.2    Scher, H.I.3    Fizazi, K.4    Bossi, A.5    Van Den Eertwegh, A.J.6
  • 33
    • 84879601217 scopus 로고    scopus 로고
    • Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer
    • 1:CAS:528:DC%2BC3sXjslOgtL8%3D 23263823
    • Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep. 2013;15(2):98-104.
    • (2013) Curr Oncol Rep. , vol.15 , Issue.2 , pp. 98-104
    • Tang, P.A.1    Heng, D.Y.2
  • 34
    • 65849449107 scopus 로고    scopus 로고
    • Prostate cancer lesions are surrounded by FOXP3(+), PD-1(+) and B7-H1(+) lymphocyte clusters
    • 1:CAS:528:DC%2BD1MXms1WmtLk%3D 19318244
    • Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, et al. Prostate cancer lesions are surrounded by FOXP3(+), PD-1(+) and B7-H1(+) lymphocyte clusters. Eur J Cancer. 2009;45(9):1664-72.
    • (2009) Eur J Cancer. , vol.45 , Issue.9 , pp. 1664-1672
    • Ebelt, K.1    Babaryka, G.2    Frankenberger, B.3    Stief, C.G.4    Eisenmenger, W.5    Kirchner, T.6
  • 35
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • 3544539 1:CAS:528:DC%2BC38XhtV2rs7fN 22658127
    • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
    • (2012) N Engl J Med. , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3    Gettinger, S.N.4    Smith, D.C.5    McDermott, D.F.6
  • 36
    • 77954899030 scopus 로고    scopus 로고
    • Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • 1:CAS:528:DC%2BC3cXpslajtLw%3D 20516446
    • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75.
    • (2010) J Clin Oncol. , vol.28 , Issue.19 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3    Powderly, J.D.4    Picus, J.5    Sharfman, W.H.6
  • 37
    • 0242692683 scopus 로고    scopus 로고
    • Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen
    • (discussion S88-S89)
    • Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003;170(6 Pt 2):S84-8 (discussion S88-S89).
    • (2003) J Urol , vol.170 , pp. 84-S88
    • Nanus, D.M.1    Milowsky, M.I.2    Kostakoglu, L.3    Smith-Jones, P.M.4    Vallabahajosula, S.5    Goldsmith, S.J.6
  • 38
    • 22044451179 scopus 로고    scopus 로고
    • Phase i trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    • 1:CAS:528:DC%2BD2MXotFarsr0%3D 15837970
    • Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591-601.
    • (2005) J Clin Oncol. , vol.23 , Issue.21 , pp. 4591-4601
    • Bander, N.H.1    Milowsky, M.I.2    Nanus, D.M.3    Kostakoglu, L.4    Vallabhajosula, S.5    Goldsmith, S.J.6
  • 39
    • 34247645942 scopus 로고    scopus 로고
    • Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
    • 1:CAS:528:DC%2BD2sXksFOlsbg%3D 17457214
    • Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007;30(4):396-405.
    • (2007) J Immunother. , vol.30 , Issue.4 , pp. 396-405
    • Olafsen, T.1    Gu, Z.2    Sherman, M.A.3    Leyton, J.V.4    Witkosky, M.E.5    Shively, J.E.6
  • 40
    • 25844449779 scopus 로고    scopus 로고
    • Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies
    • 1:CAS:528:DC%2BD2MXhtVWitb7E 16165921
    • Essand M. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies. Acta Oncol. 2005;44(6):610-27.
    • (2005) Acta Oncol. , vol.44 , Issue.6 , pp. 610-627
    • Essand, M.1
  • 41
    • 84962247223 scopus 로고    scopus 로고
    • T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression
    • 1:CAS:528:DC%2BC2MXnslSnsQ%3D%3D 25358763
    • Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res. 2015;3(1):68-84.
    • (2015) Cancer Immunol Res. , vol.3 , Issue.1 , pp. 68-84
    • Santoro, S.P.1    Kim, S.2    Motz, G.T.3    Alatzoglou, D.4    Li, C.5    Irving, M.6
  • 42
    • 84937765737 scopus 로고    scopus 로고
    • PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models
    • 4184866 25279468
    • Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS One. 2014;9(10):e109427.
    • (2014) PLoS One. , vol.9 , Issue.10 , pp. 109427
    • Zuccolotto, G.1    Fracasso, G.2    Merlo, A.3    Montagner, I.M.4    Rondina, M.5    Bobisse, S.6
  • 43
    • 84892445176 scopus 로고    scopus 로고
    • Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy
    • 1:CAS:528:DC%2BC2cXptVehsQ%3D%3D 24174378
    • Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate. 2014;74(3):286-96.
    • (2014) Prostate. , vol.74 , Issue.3 , pp. 286-296
    • Ma, Q.1    Gomes, E.M.2    Lo, A.S.3    Junghans, R.P.4
  • 44
    • 84872196489 scopus 로고    scopus 로고
    • Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
    • 1:CAS:528:DC%2BC38XhvVersr%2FM 23242161
    • Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71-5.
    • (2013) Nat Biotechnol. , vol.31 , Issue.1 , pp. 71-75
    • Kloss, C.C.1    Condomines, M.2    Cartellieri, M.3    Bachmann, M.4    Sadelain, M.5
  • 45
    • 84892447898 scopus 로고    scopus 로고
    • Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
    • 3899402 24438073
    • Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer. 2014;14:30.
    • (2014) BMC Cancer. , vol.14 , pp. 30
    • Hillerdal, V.1    Ramachandran, M.2    Leja, J.3    Essand, M.4
  • 46
    • 34250839415 scopus 로고    scopus 로고
    • Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells
    • 1:CAS:528:DC%2BD2sXot1Kqtbk%3D 17492652
    • Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007;67(10):1121-31.
    • (2007) Prostate. , vol.67 , Issue.10 , pp. 1121-1131
    • Morgenroth, A.1    Cartellieri, M.2    Schmitz, M.3    Gunes, S.4    Weigle, B.5    Bachmann, M.6
  • 47
    • 84906508776 scopus 로고    scopus 로고
    • A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer
    • 1:CAS:528:DC%2BC2cXitV2ntrnI 24694017
    • Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014;25(12):1003-12.
    • (2014) Hum Gene Ther. , vol.25 , Issue.12 , pp. 1003-1012
    • Abate-Daga, D.1    Lagisetty, K.H.2    Tran, E.3    Zheng, Z.4    Gattinoni, L.5    Yu, Z.6
  • 48
    • 25444524262 scopus 로고    scopus 로고
    • Targeted elimination of prostate cancer by genetically directed human T lymphocytes
    • 1:CAS:528:DC%2BD2MXhtVKiu7vJ 16204083
    • Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005;65(19):9080-8.
    • (2005) Cancer Res. , vol.65 , Issue.19 , pp. 9080-9088
    • Gade, T.P.1    Hassen, W.2    Santos, E.3    Gunset, G.4    Saudemont, A.5    Gong, M.C.6
  • 49
    • 0036137615 scopus 로고    scopus 로고
    • Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor
    • 1:CAS:528:DC%2BD38XislSktw%3D%3D 11753365
    • Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20(1):70-5.
    • (2002) Nat Biotechnol. , vol.20 , Issue.1 , pp. 70-75
    • Maher, J.1    Brentjens, R.J.2    Gunset, G.3    Riviere, I.4    Sadelain, M.5
  • 50
    • 79955631811 scopus 로고    scopus 로고
    • Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats
    • 1:CAS:528:DC%2BC3MXlsV2nurY%3D 21541976
    • Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71(9):998-1011.
    • (2011) Prostate. , vol.71 , Issue.9 , pp. 998-1011
    • Feldmann, A.1    Stamova, S.2    Bippes, C.C.3    Bartsch, H.4    Wehner, R.5    Schmitz, M.6
  • 51
    • 84866159579 scopus 로고    scopus 로고
    • Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells
    • 1:CAS:528:DC%2BC38XhtlWqsb3J 22875801
    • Feldmann A, Arndt C, Topfer K, Stamova S, Krone F, Cartellieri M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol. 2012;189(6):3249-59.
    • (2012) J Immunol. , vol.189 , Issue.6 , pp. 3249-3259
    • Feldmann, A.1    Arndt, C.2    Topfer, K.3    Stamova, S.4    Krone, F.5    Cartellieri, M.6
  • 52
    • 84905905975 scopus 로고    scopus 로고
    • Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system
    • 1:CAS:528:DC%2BC2cXhtlaisLzE 25053443
    • Arndt C, Feldmann A, Koristka S, Cartellieri M, Dimmel M, Ehninger A, et al. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. Prostate. 2014;74(13):1335-46.
    • (2014) Prostate. , vol.74 , Issue.13 , pp. 1335-1346
    • Arndt, C.1    Feldmann, A.2    Koristka, S.3    Cartellieri, M.4    Dimmel, M.5    Ehninger, A.6
  • 53
    • 84905915818 scopus 로고    scopus 로고
    • Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells
    • 1:CAS:528:DC%2BC2cXhtlaisLrM 25053504
    • Arndt C, Feldmann A, Topfer K, Koristka S, Cartellieri M, Temme A, et al. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells. Prostate. 2014;74(13):1347-58.
    • (2014) Prostate. , vol.74 , Issue.13 , pp. 1347-1358
    • Arndt, C.1    Feldmann, A.2    Topfer, K.3    Koristka, S.4    Cartellieri, M.5    Temme, A.6
  • 54
    • 84871546145 scopus 로고    scopus 로고
    • Antitumor activities of PSMA × CD3 diabodies by redirected T-cell lysis of prostate cancer cells
    • 1:CAS:528:DC%2BC38XhvVKgsLjJ 23256796
    • Baum V, Buhler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, et al. Antitumor activities of PSMA × CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013;5(1):27-38.
    • (2013) Immunotherapy. , vol.5 , Issue.1 , pp. 27-38
    • Baum, V.1    Buhler, P.2    Gierschner, D.3    Herchenbach, D.4    Fiala, G.J.5    Schamel, W.W.6
  • 55
    • 84871360414 scopus 로고    scopus 로고
    • Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens
    • 1:CAS:528:DC%2BC38XhvVSqt7bL 23041545
    • Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012;11(12):2664-73.
    • (2012) Mol Cancer Ther. , vol.11 , Issue.12 , pp. 2664-2673
    • Friedrich, M.1    Raum, T.2    Lutterbuese, R.3    Voelkel, M.4    Deegen, P.5    Rau, D.6
  • 56
    • 79952380566 scopus 로고    scopus 로고
    • Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody
    • 20945402
    • Fortmuller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody. Prostate. 2011;71(6):588-96.
    • (2011) Prostate. , vol.71 , Issue.6 , pp. 588-596
    • Fortmuller, K.1    Alt, K.2    Gierschner, D.3    Wolf, P.4    Baum, V.5    Freudenberg, N.6
  • 57
    • 67651171654 scopus 로고    scopus 로고
    • Target-dependent T-cell activation by coligation with a PSMA × CD3 diabody induces lysis of prostate cancer cells
    • Buhler P, Molnar E, Dopfer EP, Wolf P, Gierschner D, Wetterauer U, et al. Target-dependent T-cell activation by coligation with a PSMA × CD3 diabody induces lysis of prostate cancer cells. J Immunother. 2009;32(6):565-73.
    • (2009) J Immunother. , vol.32 , Issue.6 , pp. 565-573
    • Buhler, P.1    Molnar, E.2    Dopfer, E.P.3    Wolf, P.4    Gierschner, D.5    Wetterauer, U.6
  • 58
    • 35748956820 scopus 로고    scopus 로고
    • A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
    • 2755730 1:STN:280:DC%2BD2snktV2isA%3D%3D 17579857
    • Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother. 2008;57(1):43-52.
    • (2008) Cancer Immunol Immunother. , vol.57 , Issue.1 , pp. 43-52
    • Buhler, P.1    Wolf, P.2    Gierschner, D.3    Schaber, I.4    Katzenwadel, A.5    Schultze-Seemann, W.6
  • 59
    • 0027717345 scopus 로고
    • Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
    • 1:STN:280:DyaK3szktlWqtQ%3D%3D 7688183
    • Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143(2):401-9.
    • (1993) Am J Pathol. , vol.143 , Issue.2 , pp. 401-409
    • Weidner, N.1    Carroll, P.R.2    Flax, J.3    Blumenfeld, W.4    Folkman, J.5
  • 60
    • 84928705533 scopus 로고    scopus 로고
    • VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
    • 1:CAS:528:DC%2BC2MXptVCqsQ%3D%3D 25361735
    • Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J. 2015;29(1):227-38.
    • (2015) FASEB J. , vol.29 , Issue.1 , pp. 227-238
    • Huang, H.1    Langenkamp, E.2    Georganaki, M.3    Loskog, A.4    Fuchs, P.F.5    Dieterich, L.C.6
  • 61
    • 4043157141 scopus 로고    scopus 로고
    • Metastatic properties of prostate cancer cells are controlled by VEGF
    • Chen J, De S, Brainard J, Byzova TV. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes. 2004;11(1):1-11.
    • (2004) Cell Commun Adhes. , vol.11 , Issue.1 , pp. 1-11
    • Chen, J.1    De, S.2    Brainard, J.3    Byzova, T.V.4
  • 62
    • 84901206080 scopus 로고    scopus 로고
    • The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton
    • 3874956 24396604
    • Roberts E, Cossigny DA, Quan GM. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer. 2013;2013:418340.
    • (2013) Prostate Cancer. , vol.2013 , pp. 418340
    • Roberts, E.1    Cossigny, D.A.2    Quan, G.M.3
  • 63
    • 84882550346 scopus 로고    scopus 로고
    • Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature
    • 23982676
    • Shi S, Chen L, Huang G. Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature. Med Oncol. 2013;30(4):698.
    • (2013) Med Oncol. , vol.30 , Issue.4 , pp. 698
    • Shi, S.1    Chen, L.2    Huang, G.3
  • 64
    • 84879058083 scopus 로고    scopus 로고
    • Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models
    • 3683034 1:CAS:528:DC%2BC3sXhtVCmsrvM 23799045
    • Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One. 2013;8(6):e65757.
    • (2013) PLoS One. , vol.8 , Issue.6 , pp. 65757
    • Shi, S.1    Wang, R.2    Chen, Y.3    Song, H.4    Chen, L.5    Huang, G.6
  • 65
    • 84867902940 scopus 로고    scopus 로고
    • Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
    • 3491458 1:CAS:528:DC%2BC38XhvVSltLjK 23045683
    • Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci. 2012;109(43):17561-6.
    • (2012) Proc Natl Acad Sci , vol.109 , Issue.43 , pp. 17561-17566
    • Huang, Y.1    Yuan, J.2    Righi, E.3    Kamoun, W.S.4    Ancukiewicz, M.5    Nezivar, J.6
  • 66
    • 36348942363 scopus 로고    scopus 로고
    • Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer
    • Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nahrig J, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 2008;57(2):271-80.
    • (2008) Cancer Immunol Immunother. , vol.57 , Issue.2 , pp. 271-280
    • Bernhard, H.1    Neudorfer, J.2    Gebhard, K.3    Conrad, H.4    Hermann, C.5    Nahrig, J.6
  • 67
    • 15244358572 scopus 로고    scopus 로고
    • Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
    • 535069 1:CAS:528:DC%2BD2cXhtFaiur%2FP 15599402
    • Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114(12):1774-81.
    • (2004) J Clin Invest. , vol.114 , Issue.12 , pp. 1774-1781
    • Pinthus, J.H.1    Waks, T.2    Malina, V.3    Kaufman-Francis, K.4    Harmelin, A.5    Aizenberg, I.6
  • 68
    • 0029833943 scopus 로고    scopus 로고
    • A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
    • 1:CAS:528:DyaK28XlsFaltb0%3D 9064327
    • Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184(3):1101-9.
    • (1996) J Exp Med. , vol.184 , Issue.3 , pp. 1101-1109
    • Bleul, C.C.1    Fuhlbrigge, R.C.2    Casasnovas, J.M.3    Aiuti, A.4    Springer, T.A.5
  • 69
    • 0034657176 scopus 로고    scopus 로고
    • Effects of continuous exposure to stromal cell-derived factor-1 alpha on T cell rolling and tight adhesion to monolayers of activated endothelial cells
    • 1:CAS:528:DC%2BD3cXjt1Glu70%3D 10799858
    • Kantele JM, Kurk S, Jutila MA. Effects of continuous exposure to stromal cell-derived factor-1 alpha on T cell rolling and tight adhesion to monolayers of activated endothelial cells. J Immunol. 2000;164(10):5035-40.
    • (2000) J Immunol. , vol.164 , Issue.10 , pp. 5035-5040
    • Kantele, J.M.1    Kurk, S.2    Jutila, M.A.3
  • 70
    • 77950882020 scopus 로고    scopus 로고
    • The CXCR4/SDF-1 chemokine axis: A potential therapeutic target for bone metastases?
    • 1:CAS:528:DC%2BC3cXlvFymuro%3D 20166978
    • Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des. 2010;16(11):1284-90.
    • (2010) Curr Pharm Des. , vol.16 , Issue.11 , pp. 1284-1290
    • Hirbe, A.C.1    Morgan, E.A.2    Weilbaecher, K.N.3
  • 71
    • 84937763170 scopus 로고    scopus 로고
    • Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer
    • 4298820 25606566
    • Lee JY, Kang DH, Chung DY, Kwon JK, Lee H, Cho NH, et al. Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer. World J Mens Health. 2014;32(3):167-75.
    • (2014) World J Mens Health. , vol.32 , Issue.3 , pp. 167-175
    • Lee, J.Y.1    Kang, D.H.2    Chung, D.Y.3    Kwon, J.K.4    Lee, H.5    Cho, N.H.6
  • 72
    • 84874141705 scopus 로고    scopus 로고
    • Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor
    • 3575507 1:CAS:528:DC%2BC3sXjsFShsrY%3D 23441216
    • Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One. 2013;8(2):e56820.
    • (2013) PLoS One. , vol.8 , Issue.2 , pp. 56820
    • Asai, H.1    Fujiwara, H.2    An, J.3    Ochi, T.4    Miyazaki, Y.5    Nagai, K.6
  • 73
    • 79960403269 scopus 로고    scopus 로고
    • Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor
    • 3612507 1:CAS:528:DC%2BC3MXovFeht7o%3D 21610146
    • Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719-30.
    • (2011) Clin Cancer Res. , vol.17 , Issue.14 , pp. 4719-4730
    • Moon, E.K.1    Carpenito, C.2    Sun, J.3    Wang, L.C.4    Kapoor, V.5    Predina, J.6
  • 74
    • 77958063691 scopus 로고    scopus 로고
    • Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b
    • 2998197 1:CAS:528:DC%2BC3cXht1WjurfL 20842059
    • Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780-8.
    • (2010) J Immunother. , vol.33 , Issue.8 , pp. 780-788
    • Craddock, J.A.1    Lu, A.2    Bear, A.3    Pule, M.4    Brenner, M.K.5    Rooney, C.M.6
  • 75
    • 77549086214 scopus 로고    scopus 로고
    • CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
    • 2857769 1:CAS:528:DC%2BC3cXivFKgsrc%3D 20005149
    • Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21(1):41-8.
    • (2010) Cytokine Growth Factor Rev. , vol.21 , Issue.1 , pp. 41-48
    • Zhang, J.1    Patel, L.2    Pienta, K.J.3
  • 76
    • 84875547888 scopus 로고    scopus 로고
    • Chemokines and chemokine receptors as promoters of prostate cancer growth and progression
    • 1:CAS:528:DC%2BC3sXnvVGntLs%3D
    • Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukar Gene. 2013;23(1):77-91.
    • (2013) Crit Rev Eukar Gene. , vol.23 , Issue.1 , pp. 77-91
    • Salazar, N.1    Castellan, M.2    Shirodkar, S.S.3    Lokeshwar, B.L.4
  • 77
    • 67650638846 scopus 로고    scopus 로고
    • T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
    • 2710932 19377047
    • Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392-402.
    • (2009) Blood. , vol.113 , Issue.25 , pp. 6392-6402
    • Di Stasi, A.1    De Angelis, B.2    Rooney, C.M.3    Zhang, L.4    Mahendravada, A.5    Foster, A.E.6
  • 78
    • 38949140177 scopus 로고    scopus 로고
    • Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment
    • 1:CAS:528:DC%2BD1MXjs1ygtbg%3D 18271931
    • Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, et al. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci. 2008;99(2):316-23.
    • (2008) Cancer Sci. , vol.99 , Issue.2 , pp. 316-323
    • Sato, S.1    Futakuchi, M.2    Ogawa, K.3    Asamoto, M.4    Nakao, K.5    Asai, K.6
  • 79
    • 81255176525 scopus 로고    scopus 로고
    • Immune regulation of the tumor/bone vicious cycle
    • 1:CAS:528:DC%2BC38Xns1Kkuw%3D%3D 22082368
    • Faccio R. Immune regulation of the tumor/bone vicious cycle. Ann N Y Acad Sci. 2011;1237:71-8.
    • (2011) Ann N y Acad Sci. , vol.1237 , pp. 71-78
    • Faccio, R.1
  • 80
    • 84877975744 scopus 로고    scopus 로고
    • Interaction among cells of bone, immune system, and solid tumors leads to bone metastases
    • 3655477 23710201
    • Roato I. Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. Clin Dev Immunol. 2013;2013:315024.
    • (2013) Clin Dev Immunol. , vol.2013 , pp. 315024
    • Roato, I.1
  • 81
    • 33947203783 scopus 로고    scopus 로고
    • CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack
    • 1:CAS:528:DC%2BD2sXitlSjsL4%3D 17332357
    • Koehler H, Kofler D, Hombach A, Abken H. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res. 2007;67(5):2265-73.
    • (2007) Cancer Res. , vol.67 , Issue.5 , pp. 2265-2273
    • Koehler, H.1    Kofler, D.2    Hombach, A.3    Abken, H.4
  • 82
    • 0036566184 scopus 로고    scopus 로고
    • Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity
    • 1:CAS:528:DC%2BD38XjtlGqsrk%3D 11964281
    • Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99(9):3179-87.
    • (2002) Blood. , vol.99 , Issue.9 , pp. 3179-3187
    • Bollard, C.M.1    Rossig, C.2    Calonge, M.J.3    Huls, M.H.4    Wagner, H.J.5    Massague, J.6
  • 83
    • 80051698813 scopus 로고    scopus 로고
    • Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice
    • 3176721 1:CAS:528:DC%2BC3MXhtVajs7nM 21737507
    • Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 2011;17(16):5343-52.
    • (2011) Clin Cancer Res. , vol.17 , Issue.16 , pp. 5343-5352
    • Klebanoff, C.A.1    Gattinoni, L.2    Palmer, D.C.3    Muranski, P.4    Ji, Y.5    Hinrichs, C.S.6
  • 84
    • 84877788719 scopus 로고    scopus 로고
    • Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy
    • 1:CAS:528:DC%2BC38XhtlertbvL 22972494
    • Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, et al. Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 2013;20(5):575-80.
    • (2013) Gene Ther. , vol.20 , Issue.5 , pp. 575-580
    • Zhang, L.1    Yu, Z.2    Muranski, P.3    Palmer, D.C.4    Restifo, N.P.5    Rosenberg, S.A.6
  • 85
    • 84875469804 scopus 로고    scopus 로고
    • Adoptive immunotherapy with redirected T cells produces CCR7(-) cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation
    • 1:CAS:528:DC%2BC3sXktleltbk%3D 23350854
    • Hombach AA, Chmielewski M, Rappl G, Abken H. Adoptive immunotherapy with redirected T cells produces CCR7(-) cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther. 2013;24(3):259-69.
    • (2013) Hum Gene Ther. , vol.24 , Issue.3 , pp. 259-269
    • Hombach, A.A.1    Chmielewski, M.2    Rappl, G.3    Abken, H.4
  • 86
    • 0034812971 scopus 로고    scopus 로고
    • OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells
    • 1:CAS:528:DC%2BD3MXntlSntb8%3D 11567634
    • Rogers PR, Song JX, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15(3):445-55.
    • (2001) Immunity. , vol.15 , Issue.3 , pp. 445-455
    • Rogers, P.R.1    Song, J.X.2    Gramaglia, I.3    Killeen, N.4    Croft, M.5
  • 87
    • 84861674447 scopus 로고    scopus 로고
    • Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies
    • 3360496 1:CAS:528:DC%2BC38XnslKmsL0%3D 22107246
    • Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23(5):444-50.
    • (2012) Hum Gene Ther. , vol.23 , Issue.5 , pp. 444-450
    • Kebriaei, P.1    Huls, H.2    Jena, B.3    Munsell, M.4    Jackson, R.5    Lee, D.A.6
  • 88
    • 17844381006 scopus 로고    scopus 로고
    • Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
    • 2174599 1:CAS:528:DC%2BD2MXjtlKksro%3D 15838383
    • Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28(3):258-67.
    • (2005) J Immunother. , vol.28 , Issue.3 , pp. 258-267
    • Huang, J.1    Khong, H.T.2    Dudley, M.E.3    El-Gamil, M.4    Li, Y.F.5    Rosenberg, S.A.6
  • 89
    • 84865744445 scopus 로고    scopus 로고
    • CAR T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
    • 1:CAS:528:DC%2BC38XhtVOhtL7P 22274776
    • Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012;61(8):1269-77.
    • (2012) Cancer Immunol Immunother. , vol.61 , Issue.8 , pp. 1269-1277
    • Chmielewski, M.1    Abken, H.2
  • 90
    • 84890179288 scopus 로고    scopus 로고
    • Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
    • Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83-90.
    • (2013) Immunol Rev. , vol.257 , Issue.1 , pp. 83-90
    • Chmielewski, M.1    Hombach, A.A.2    Abken, H.3
  • 91
    • 80052257433 scopus 로고    scopus 로고
    • IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression
    • 1:CAS:528:DC%2BC3MXhtFSmtbrO 21742772
    • Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697-706.
    • (2011) Cancer Res. , vol.71 , Issue.17 , pp. 5697-5706
    • Chmielewski, M.1    Kopecky, C.2    Hombach, A.A.3    Abken, H.4
  • 92
    • 84863230570 scopus 로고    scopus 로고
    • Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice
    • 1:CAS:528:DC%2BC38XktVynu7c%3D 22291136
    • Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res. 2012;18(6):1672-83.
    • (2012) Clin Cancer Res. , vol.18 , Issue.6 , pp. 1672-1683
    • Chinnasamy, D.1    Yu, Z.2    Kerkar, S.P.3    Zhang, L.4    Morgan, R.A.5    Restifo, N.P.6
  • 93
    • 84858759305 scopus 로고    scopus 로고
    • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
    • 3359735 1:CAS:528:DC%2BC38XmvV2rsLg%3D 22354001
    • Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133-41.
    • (2012) Blood. , vol.119 , Issue.18 , pp. 4133-4141
    • Pegram, H.J.1    Lee, J.C.2    Hayman, E.G.3    Imperato, G.H.4    Tedder, T.F.5    Sadelain, M.6
  • 94
    • 84922544653 scopus 로고    scopus 로고
    • IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
    • 1:CAS:528:DC%2BC2cXht1Gru7zJ 25005243
    • Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29(2):415-22.
    • (2015) Leukemia. , vol.29 , Issue.2 , pp. 415-422
    • Pegram, H.J.1    Purdon, T.J.2    Van Leeuwen, D.G.3    Curran, K.J.4    Giralt, S.A.5    Barker, J.N.6
  • 95
    • 84886397930 scopus 로고    scopus 로고
    • Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells
    • 1:CAS:528:DC%2BC3sXhs1ahurrJ 23873688
    • John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636-46.
    • (2013) Clin Cancer Res. , vol.19 , Issue.20 , pp. 5636-5646
    • John, L.B.1    Devaud, C.2    Duong, C.P.3    Yong, C.S.4    Beavis, P.A.5    Haynes, N.M.6
  • 96
    • 84862502741 scopus 로고    scopus 로고
    • Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models
    • 1:CAS:528:DC%2BC38XhtVGns7%2FN 22538857
    • Shin JH, Park HB, Oh YM, Lim DP, Lee JE, Seo HH, et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood. 2012;119(24):5678-87.
    • (2012) Blood. , vol.119 , Issue.24 , pp. 5678-5687
    • Shin, J.H.1    Park, H.B.2    Oh, Y.M.3    Lim, D.P.4    Lee, J.E.5    Seo, H.H.6
  • 97
    • 84899081871 scopus 로고    scopus 로고
    • Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands
    • 3976982 24711957
    • Ankri C, Cohen CJ. Out of the bitter came forth sweet: activating CD28-dependent co-stimulation via PD-1 ligands. Oncoimmunology. 2014;3(1):e27399.
    • (2014) Oncoimmunology. , vol.3 , Issue.1 , pp. 27399
    • Ankri, C.1    Cohen, C.J.2
  • 98
    • 84902146901 scopus 로고    scopus 로고
    • Reversal of tumor immune inhibition using a chimeric cytokine receptor
    • 1:CAS:528:DC%2BC2cXmtlWgsr8%3D 24732709
    • Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014;22(6):1211-20.
    • (2014) Mol Ther. , vol.22 , Issue.6 , pp. 1211-1220
    • Leen, A.M.1    Sukumaran, S.2    Watanabe, N.3    Mohammed, S.4    Keirnan, J.5    Yanagisawa, R.6
  • 99
    • 82955207691 scopus 로고    scopus 로고
    • Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
    • 3234664 1:CAS:528:DC%2BC3MXhs1ansb3O 21984804
    • Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6.
    • (2011) Blood. , vol.118 , Issue.23 , pp. 6050-6056
    • Louis, C.U.1    Savoldo, B.2    Dotti, G.3    Pule, M.4    Yvon, E.5    Myers, G.D.6
  • 100
    • 84910049723 scopus 로고    scopus 로고
    • Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
    • 4253438 25344864
    • Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014;5(19):9335-48.
    • (2014) Oncotarget. , vol.5 , Issue.19 , pp. 9335-9348
    • Ardiani, A.1    Gameiro, S.R.2    Kwilas, A.R.3    Donahue, R.N.4    Hodge, J.W.5
  • 101
    • 84903977462 scopus 로고    scopus 로고
    • Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation
    • 4103356 1:CAS:528:DC%2BC2cXhtVaisrnF 24958858
    • Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci. 2014;111(27):9887-92.
    • (2014) Proc Natl Acad Sci , vol.111 , Issue.27 , pp. 9887-9892
    • Kissick, H.T.1    Sanda, M.G.2    Dunn, L.K.3    Pellegrini, K.L.4    On, S.T.5    Noel, J.K.6
  • 102
    • 85015703065 scopus 로고    scopus 로고
    • Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
    • 1:CAS:528:DC%2BC2cXos1OlsL4%3D
    • Jin C, Yu D, Hillerdal V, Wallgren AC, Karlsson-Parra A, Essand M. Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2014;1:14001. doi: 10.1038/mtm.2014.1.
    • (2014) Mol Ther Methods Clin Dev. , vol.1 , pp. 14001
    • Jin, C.1    Yu, D.2    Hillerdal, V.3    Wallgren, A.C.4    Karlsson-Parra, A.5    Essand, M.6
  • 103
    • 84890827981 scopus 로고    scopus 로고
    • Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
    • 3862276 1:CAS:528:DC%2BC3sXhvFOqsr7P 24055823
    • Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-39.
    • (2013) Blood. , vol.122 , Issue.25 , pp. 4129-4139
    • Kochenderfer, J.N.1    Dudley, M.E.2    Carpenter, R.O.3    Kassim, S.H.4    Rose, J.J.5    Telford, W.G.6
  • 104
    • 84891832317 scopus 로고    scopus 로고
    • Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
    • 1:CAS:528:DC%2BC3sXhs12lt7zP 24141191
    • Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343(2):172-8.
    • (2014) Cancer Lett. , vol.343 , Issue.2 , pp. 172-178
    • Xu, X.J.1    Tang, Y.M.2
  • 105
    • 84895066532 scopus 로고    scopus 로고
    • Toxicity management for patients receiving novel T-cell engaging therapies
    • 4198063 1:CAS:528:DC%2BC2cXnsVKmuw%3D%3D 24362408
    • Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26(1):43-9.
    • (2014) Curr Opin Pediatr. , vol.26 , Issue.1 , pp. 43-49
    • Barrett, D.M.1    Teachey, D.T.2    Grupp, S.A.3
  • 106
    • 84876005284 scopus 로고    scopus 로고
    • CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
    • 3742551 23515080
    • Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
    • (2013) Sci Transl Med. , vol.5 , Issue.177 , pp. 177ra38
    • Brentjens, R.J.1    Davila, M.L.2    Riviere, I.3    Park, J.4    Wang, X.5    Cowell, L.G.6
  • 107
    • 84863337890 scopus 로고    scopus 로고
    • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    • 3327450 1:CAS:528:DC%2BC38XkvFalt7o%3D 22160384
    • Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-20.
    • (2012) Blood. , vol.119 , Issue.12 , pp. 2709-2720
    • Kochenderfer, J.N.1    Dudley, M.E.2    Feldman, S.A.3    Wilson, W.H.4    Spaner, D.E.5    Maric, I.6
  • 108
    • 84890207337 scopus 로고    scopus 로고
    • T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
    • 3888798 1:CAS:528:DC%2BC2cXmtFSjtLo%3D
    • Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu XJ, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26-31.
    • (2013) Cancer Immunol Res. , vol.1 , Issue.1 , pp. 26-31
    • Maus, M.V.1    Haas, A.R.2    Beatty, G.L.3    Albelda, S.M.4    Levine, B.L.5    Liu, X.J.6
  • 109
    • 84901706683 scopus 로고    scopus 로고
    • At the bedside: Adoptive cell therapy for melanoma-clinical development
    • 24732024
    • Weber JS. At the bedside: adoptive cell therapy for melanoma-clinical development. J Leukocyte Biol. 2014;95(6):875-82.
    • (2014) J Leukocyte Biol. , vol.95 , Issue.6 , pp. 875-882
    • Weber, J.S.1
  • 110
    • 33646440024 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
    • Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-2.
    • (2006) J Clin Oncol. , vol.24 , Issue.13 , pp. 20-e22
    • Lamers, C.H.1    Sleijfer, S.2    Vulto, A.G.3    Kruit, W.H.4    Kliffen, M.5    Debets, R.6
  • 111
    • 33750699642 scopus 로고    scopus 로고
    • A phase i study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
    • 2154351 1:CAS:528:DC%2BD28XhtFWhsbnL 17062687
    • Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-15.
    • (2006) Clin Cancer Res. , vol.12 , pp. 6106-6115
    • Kershaw, M.H.1    Westwood, J.A.2    Parker, L.L.3    Wang, G.4    Eshhar, Z.5    Mavroukakis, S.A.6
  • 112
    • 84878605813 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity
    • 1:CAS:528:DC%2BC3sXislWhtbw%3D 23423337
    • Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904-12.
    • (2013) Mol Ther. , vol.21 , Issue.4 , pp. 904-912
    • Lamers, C.H.1    Sleijfer, S.2    Van Steenbergen, S.3    Van Elzakker, P.4    Van Krimpen, B.5    Groot, C.6
  • 113
    • 33947265424 scopus 로고    scopus 로고
    • Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
    • 1:CAS:528:DC%2BD2sXhtVejtLfF 17299405
    • Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825-33.
    • (2007) Mol Ther. , vol.15 , Issue.4 , pp. 825-833
    • Park, J.R.1    Digiusto, D.L.2    Slovak, M.3    Wright, C.4    Naranjo, A.5    Wagner, J.6
  • 114
    • 77950475517 scopus 로고    scopus 로고
    • Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
    • 2862534 1:CAS:528:DC%2BC3cXitlaitb4%3D 20179677
    • Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-51.
    • (2010) Mol Ther. , vol.18 , Issue.4 , pp. 843-851
    • Morgan, R.A.1    Yang, J.C.2    Kitano, M.3    Dudley, M.E.4    Laurencot, C.M.5    Rosenberg, S.A.6
  • 115
    • 84866740895 scopus 로고    scopus 로고
    • Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling
    • 1:CAS:528:DC%2BC38XhtlOlurjL 22526592
    • Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059-70.
    • (2012) J Clin Immunol. , vol.32 , Issue.5 , pp. 1059-1070
    • Wilkie, S.1    Van Schalkwyk, M.C.2    Hobbs, S.3    Davies, D.M.4    Van Der Stegen, S.J.5    Pereira, A.C.6
  • 116
    • 84890174110 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo
    • 3881605 1:CAS:528:DC%2BC2cXmtFSjtLY%3D 24409448
    • Lanitis E, Poussin M, Klattenhoff AW, Song DG, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43-53.
    • (2013) Cancer Immunol Res. , vol.1 , Issue.1 , pp. 43-53
    • Lanitis, E.1    Poussin, M.2    Klattenhoff, A.W.3    Song, D.G.4    Sandaltzopoulos, R.5    June, C.H.6
  • 117
    • 84908700977 scopus 로고    scopus 로고
    • The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
    • 4211380 25389405
    • Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
    • (2014) Front Pharmacol. , vol.5 , pp. 235
    • Gargett, T.1    Brown, M.P.2
  • 119
    • 84862496486 scopus 로고    scopus 로고
    • A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
    • 3382929 1:CAS:528:DC%2BC38XhtVGns7%2FP 22535661
    • Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697-705.
    • (2012) Blood. , vol.119 , Issue.24 , pp. 5697-5705
    • Torikai, H.1    Reik, A.2    Liu, P.Q.3    Zhou, Y.4    Zhang, L.5    Maiti, S.6
  • 120
    • 84902084418 scopus 로고    scopus 로고
    • TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
    • 1:CAS:528:DC%2BC2cXkvF2mu7g%3D 24670996
    • Berdien B, Mock U, Atanackovic D, Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014;21(6):539-48.
    • (2014) Gene Ther. , vol.21 , Issue.6 , pp. 539-548
    • Berdien, B.1    Mock, U.2    Atanackovic, D.3    Fehse, B.4
  • 121
    • 84902096048 scopus 로고    scopus 로고
    • Development and applications of CRISPR-Cas9 for genome engineering
    • 4343198 1:CAS:528:DC%2BC2cXpslagt7s%3D 24906146
    • Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-78.
    • (2014) Cell. , vol.157 , Issue.6 , pp. 1262-1278
    • Hsu, P.D.1    Lander, E.S.2    Zhang, F.3
  • 122
    • 84870309981 scopus 로고    scopus 로고
    • Redirecting gene-modified T cells toward various cancer types using tagged antibodies
    • 1:CAS:528:DC%2BC38XhslKgurjJ 23032741
    • Tamada K, Geng DG, Sakoda Y, Bansal N, Srivastava R, Li ZY, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18(23):6436-45.
    • (2012) Clin Cancer Res. , vol.18 , Issue.23 , pp. 6436-6445
    • Tamada, K.1    Geng, D.G.2    Sakoda, Y.3    Bansal, N.4    Srivastava, R.5    Li, Z.Y.6
  • 123
    • 84875226632 scopus 로고    scopus 로고
    • Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor
    • 3589159 1:CAS:528:DC%2BC3sXkt1Wjuw%3D%3D 23295945
    • Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013;21(3):638-47.
    • (2013) Mol Ther. , vol.21 , Issue.3 , pp. 638-647
    • Deniger, D.C.1    Switzer, K.2    Mi, T.3    Maiti, S.4    Hurton, L.5    Singh, H.6
  • 124
    • 84902590288 scopus 로고    scopus 로고
    • Are natural killer cells superior CAR drivers?
    • 4203506 25340009
    • Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147.
    • (2014) Oncoimmunology. , vol.3 , pp. 28147
    • Klingemann, H.1
  • 125
    • 84879480191 scopus 로고    scopus 로고
    • Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
    • 3804130 1:CAS:528:DC%2BC3sXpsVyns78%3D 23620405
    • Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153-64.
    • (2013) Clin Cancer Res. , vol.19 , Issue.12 , pp. 3153-3164
    • Hudecek, M.1    Lupo-Stanghellini, M.T.2    Kosasih, P.L.3    Sommermeyer, D.4    Jensen, M.C.5    Rader, C.6
  • 126
    • 77954472387 scopus 로고    scopus 로고
    • Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function
    • 1:CAS:528:DC%2BC3cXltVGhs7o%3D 20351194
    • Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol. 2010;184(9):4936-46.
    • (2010) J Immunol. , vol.184 , Issue.9 , pp. 4936-4946
    • Schmid, D.A.1    Irving, M.B.2    Posevitz, V.3    Hebeisen, M.4    Posevitz-Fejfar, A.5    Sarria, J.C.6
  • 127
    • 84908123708 scopus 로고    scopus 로고
    • Functional avidity-driven activation-induced cell death shapes CTL immunodominance
    • 1:CAS:528:DC%2BC2cXhslKgurjO 25246498
    • Dalla Santa S, Merlo A, Bobisse S, Ronconi E, Boldrin D, Milan G, et al. Functional avidity-driven activation-induced cell death shapes CTL immunodominance. J Immunol. 2014;193(9):4704-11.
    • (2014) J Immunol , vol.193 , Issue.9 , pp. 4704-4711
    • Dalla Santa, S.1    Merlo, A.2    Bobisse, S.3    Ronconi, E.4    Boldrin, D.5    Milan, G.6
  • 128
    • 84876859096 scopus 로고    scopus 로고
    • T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
    • 3637771 1:CAS:528:DC%2BC3sXot1Wqs74%3D 23576742
    • Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci. 2013;110(17):6973-8.
    • (2013) Proc Natl Acad Sci , vol.110 , Issue.17 , pp. 6973-6978
    • Zhong, S.1    Malecek, K.2    Johnson, L.A.3    Yu, Z.4    Vega-Saenz De Miera, E.5    Darvishian, F.6
  • 129
    • 84953344459 scopus 로고    scopus 로고
    • The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity
    • 1:CAS:528:DC%2BC2MXis1Kntbk%3D 25212991
    • Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125-35.
    • (2015) Cancer Immunol Res. , vol.3 , Issue.2 , pp. 125-135
    • Hudecek, M.1    Sommermeyer, D.2    Kosasih, P.L.3    Silva-Benedict, A.4    Liu, L.5    Rader, C.6
  • 130
    • 77957980319 scopus 로고    scopus 로고
    • Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response
    • 1:CAS:528:DC%2BC3cXnsFKjtrg%3D 20555360
    • Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 2010;17(10):1206-13.
    • (2010) Gene Ther. , vol.17 , Issue.10 , pp. 1206-1213
    • Hombach, A.1    Hombach, A.A.2    Abken, H.3
  • 131
    • 20944439742 scopus 로고    scopus 로고
    • The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
    • 1:CAS:528:DC%2BD2MXjtlKlurc%3D 15838376
    • Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors - evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203-11.
    • (2005) J Immunother. , vol.28 , Issue.3 , pp. 203-211
    • Guest, R.D.1    Hawkins, R.E.2    Kirillova, N.3    Cheadle, E.J.4    Arnold, J.5    O'Neill, A.6
  • 132
    • 77953647938 scopus 로고    scopus 로고
    • The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex
    • 1:CAS:528:DC%2BC3cXmvFejsL4%3D 20483753
    • Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938-49.
    • (2010) J Immunol. , vol.184 , Issue.12 , pp. 6938-6949
    • Bridgeman, J.S.1    Hawkins, R.E.2    Bagley, S.3    Blaylock, M.4    Holland, M.5    Gilham, D.E.6
  • 133
    • 84867746760 scopus 로고    scopus 로고
    • Genetic modification of lymphocytes by retrovirus-based vectors
    • 1:CAS:528:DC%2BC38XhtlKrs7jE 22995202
    • Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol. 2012;24(5):598-608.
    • (2012) Curr Opin Immunol. , vol.24 , Issue.5 , pp. 598-608
    • Suerth, J.D.1    Schambach, A.2    Baum, C.3
  • 134
    • 0034724857 scopus 로고    scopus 로고
    • Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
    • 1:CAS:528:DC%2BD3cXivFGhtbc%3D 10784449
    • Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-72.
    • (2000) Science. , vol.288 , Issue.5466 , pp. 669-672
    • Cavazzana-Calvo, M.1    Hacein-Bey, S.2    De Saint, B.G.3    Gross, F.4    Yvon, E.5    Nusbaum, P.6
  • 135
    • 84899683375 scopus 로고    scopus 로고
    • Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor
    • 1:CAS:528:DC%2BC2cXkt1aju7g%3D 24578496
    • Amirache F, Levy C, Costa C, Mangeot PE, Torbett BE, Wang CX, et al. Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood. 2014;123(9):1422-4.
    • (2014) Blood. , vol.123 , Issue.9 , pp. 1422-1424
    • Amirache, F.1    Levy, C.2    Costa, C.3    Mangeot, P.E.4    Torbett, B.E.5    Wang, C.X.6
  • 136
    • 58149380748 scopus 로고    scopus 로고
    • Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins
    • 1:CAS:528:DC%2BD1cXhsFWms7%2FE 18812471
    • Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood. 2008;112(13):4843-52.
    • (2008) Blood. , vol.112 , Issue.13 , pp. 4843-4852
    • Frecha, C.1    Costa, C.2    Negre, D.3    Gauthier, E.4    Russell, S.J.5    Cosset, F.L.6
  • 137
    • 84878647061 scopus 로고    scopus 로고
    • Large volume flow electroporation of mRNA: Clinical scale process
    • 1:CAS:528:DC%2BC3sXivFagsbk%3D 23296932
    • Li L, Allen C, Shivakumar R, Peshwa MV. Large volume flow electroporation of mRNA: clinical scale process. Methods Mol Biol. 2013;969:127-38.
    • (2013) Methods Mol Biol. , vol.969 , pp. 127-138
    • Li, L.1    Allen, C.2    Shivakumar, R.3    Peshwa, M.V.4
  • 138
    • 84996572349 scopus 로고    scopus 로고
    • Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies
    • 3932715 1:CAS:528:DC%2BC2cXmtFSjur8%3D 24579088
    • Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112-20.
    • (2014) Cancer Immunol Res. , vol.2 , Issue.2 , pp. 112-120
    • Beatty, G.L.1    Haas, A.R.2    Maus, M.V.3    Torigian, D.A.4    Soulen, M.C.5    Plesa, G.6
  • 139
    • 84928590838 scopus 로고    scopus 로고
    • A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor
    • 1:CAS:528:DC%2BC2cXhtVCjt7%2FE
    • Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dorrie J, et al. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immun. 2014;63(10):999-1008.
    • (2014) Cancer Immunol Immun. , vol.63 , Issue.10 , pp. 999-1008
    • Krug, C.1    Wiesinger, M.2    Abken, H.3    Schuler-Thurner, B.4    Schuler, G.5    Dorrie, J.6
  • 140
    • 30444432097 scopus 로고    scopus 로고
    • Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system
    • 1:CAS:528:DC%2BD28Xms1emtA%3D%3D 16189271
    • Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood. 2006;107(2):483-91.
    • (2006) Blood. , vol.107 , Issue.2 , pp. 483-491
    • Huang, X.1    Wilber, A.C.2    Bao, L.3    Tuong, D.4    Tolar, J.5    Orchard, P.J.6
  • 141
    • 39849086801 scopus 로고    scopus 로고
    • Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19(+) lymphoid malignancies
    • 1:CAS:528:DC%2BD1cXisFOrsrs%3D 18227839
    • Huang X, Guo HF, Kang J, Choi S, Zhou TC, Tammana S, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19(+) lymphoid malignancies. Mol Ther. 2008;16(3):580-9.
    • (2008) Mol Ther. , vol.16 , Issue.3 , pp. 580-589
    • Huang, X.1    Guo, H.F.2    Kang, J.3    Choi, S.4    Zhou, T.C.5    Tammana, S.6
  • 142
    • 42349088534 scopus 로고    scopus 로고
    • Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system
    • 2424272 1:CAS:528:DC%2BD1cXks1Ghsrw%3D 18413766
    • Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68(8):2961-71.
    • (2008) Cancer Res. , vol.68 , Issue.8 , pp. 2961-2971
    • Singh, H.1    Manuri, P.R.2    Olivares, S.3    Dara, N.4    Dawson, M.J.5    Huls, H.6
  • 143
    • 33749519601 scopus 로고    scopus 로고
    • Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor
    • 1:CAS:528:DC%2BD28XhtVans7%2FI 17015756
    • Hombach A, Kohler H, Rappl G, Abken H. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol. 2006;177(8):5668-75.
    • (2006) J Immunol. , vol.177 , Issue.8 , pp. 5668-5675
    • Hombach, A.1    Kohler, H.2    Rappl, G.3    Abken, H.4
  • 144
    • 79952236166 scopus 로고    scopus 로고
    • A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells
    • 3048898 1:CAS:528:DC%2BC3MXksVGqurc%3D 21044089
    • Berger C, Berger M, Anderson D, Riddell SR. A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol. 2011;40(2):88-103.
    • (2011) J Med Primatol. , vol.40 , Issue.2 , pp. 88-103
    • Berger, C.1    Berger, M.2    Anderson, D.3    Riddell, S.R.4
  • 145
    • 70350458112 scopus 로고    scopus 로고
    • Adoptively transferred effector cells derived from naive rather than central memory CD8(+) T cells mediate superior antitumor immunity
    • 2762661 1:CAS:528:DC%2BD1MXhs1WktrfI 19805141
    • Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu ZY, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8(+) T cells mediate superior antitumor immunity. Proc Natl Acad Sci. 2009;106(41):17469-74.
    • (2009) Proc Natl Acad Sci. , vol.106 , Issue.41 , pp. 17469-17474
    • Hinrichs, C.S.1    Borman, Z.A.2    Cassard, L.3    Gattinoni, L.4    Spolski, R.5    Yu, Z.Y.6
  • 146
    • 80053997259 scopus 로고    scopus 로고
    • A human memory T cell subset with stem cell-like properties
    • 3192229 1:CAS:528:DC%2BC3MXhtFyls7bJ 21926977
    • Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-7.
    • (2011) Nat Med. , vol.17 , Issue.10 , pp. 1290-1297
    • Gattinoni, L.1    Lugli, E.2    Ji, Y.3    Pos, Z.4    Paulos, C.M.5    Quigley, M.F.6
  • 147
    • 84904898883 scopus 로고    scopus 로고
    • Big bang theory of stem-like T cells confirmed
    • 4110654 1:CAS:528:DC%2BC2cXht1Ggu77L 25061170
    • Restifo NP. Big bang theory of stem-like T cells confirmed. Blood. 2014;124(4):476-7.
    • (2014) Blood. , vol.124 , Issue.4 , pp. 476-477
    • Restifo, N.P.1
  • 148
    • 84923912770 scopus 로고    scopus 로고
    • Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
    • 4318439 25636521
    • Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015;16(1):1.
    • (2015) BMC Immunol. , vol.16 , Issue.1 , pp. 1
    • Deng, Z.1    Wu, Y.2    Ma, W.3    Zhang, S.4    Zhang, Y.Q.5
  • 149
    • 84882449121 scopus 로고    scopus 로고
    • Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer
    • 1:CAS:528:DC%2BC3sXnvFyht7g%3D 23295316 (S1)
    • Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):123-31 (S1).
    • (2013) Prostate Cancer Prostatic Dis. , vol.16 , Issue.2 , pp. 123-131
    • Sanchez, C.1    Chan, R.2    Bajgain, P.3    Rambally, S.4    Palapattu, G.5    Mims, M.6
  • 150
    • 84904052256 scopus 로고    scopus 로고
    • High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
    • 4106163 25083320
    • van Buuren MM, Calis JJ, Schumacher TN. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology. 2014;3:e28836.
    • (2014) Oncoimmunology. , vol.3 , pp. 28836
    • Van Buuren, M.M.1    Calis, J.J.2    Schumacher, T.N.3
  • 151
    • 84872841412 scopus 로고    scopus 로고
    • Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
    • 24043743
    • van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439-42.
    • (2013) J Clin Oncol. , vol.31 , Issue.32 , pp. 439-e442
    • Van Rooij, N.1    Van Buuren, M.M.2    Philips, D.3    Velds, A.4    Toebes, M.5    Heemskerk, B.6
  • 152
    • 0023547004 scopus 로고
    • Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
    • 1:STN:280:DyaL1c7jt1GmsQ%3D%3D 2449118
    • Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.
    • (1987) Anticancer Res. , vol.7 , Issue.5 B , pp. 927-935
    • Horoszewicz, J.S.1    Kawinski, E.2    Murphy, G.P.3
  • 153
    • 0031042591 scopus 로고    scopus 로고
    • Prostate-specific membrane antigen expression in normal and malignant human tissues
    • 1:STN:280:DyaK1M%2FjsFamtA%3D%3D 9815541
    • Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81-5.
    • (1997) Clin Cancer Res. , vol.3 , Issue.1 , pp. 81-85
    • Silver, D.A.1    Pellicer, I.2    Fair, W.R.3    Heston, W.D.4    Cordon-Cardo, C.5
  • 154
    • 3242742983 scopus 로고    scopus 로고
    • Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths
    • Bera TK, Huynh N, Maeda H, Sathyanarayana BK, Lee B, Pastan I. Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. Gene. 2004;4(337):45-53.
    • (2004) Gene. , vol.4 , Issue.337 , pp. 45-53
    • Bera, T.K.1    Huynh, N.2    Maeda, H.3    Sathyanarayana, B.K.4    Lee, B.5    Pastan, I.6
  • 155
    • 36849061224 scopus 로고    scopus 로고
    • Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer
    • 1:CAS:528:DC%2BD1cXlsV2qug%3D%3D 17879963
    • Olson BM, McNeel DG. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate. 2007;67(16):1729-39.
    • (2007) Prostate. , vol.67 , Issue.16 , pp. 1729-1739
    • Olson, B.M.1    McNeel, D.G.2
  • 156
    • 49649129991 scopus 로고    scopus 로고
    • Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies
    • 2682370 1:CAS:528:DC%2BD1cXnsF2gsr8%3D 18446790
    • Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 2008;38(6):1706-20.
    • (2008) Eur J Immunol. , vol.38 , Issue.6 , pp. 1706-1720
    • Epel, M.1    Carmi, I.2    Soueid-Baumgarten, S.3    Oh, S.K.4    Bera, T.5    Pastan, I.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.